Survodutide

Research use only, not for human use.

Survodutide (BI 456906) is a dual agonist of glucagon and glucagon-like peptide 1 (GLP-1) receptors (GLP Receptor) that reduces body weight in HbA1c16 diabetes.

Survodutide (BI 456906) is a potent, selective glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist with EC50s of 0.52 nM and 0.33 nM in CHO-K1 cells, respectively. Survodutide, a 29-amino-acid peptide, is a potent acylated peptide containing a C18 fatty acid. Survodutide has robust anti-obesity efficacy achieved by increasing energy expenditure and decreasing food intake.

——

Animal Model:Male C57BL6/J mice pre-fed with a 60% HFD (22 weeks)Dosage:3, 10, 20, 30 nmol/kg Administration:SC; daily; 30 days Result:Dose-dependently reduced bodyweight from baseline by up to 32% at Day 28 at a dose of 30 nmol/kg.

——

GPCR/G Protein

Glucagon Receptor

Glucagon Receptor

——

——

2805997-46-8

4231.62

C192H289N47O61

>98% (HPLC)

In Vitro:?DMSO : 100 mg/mL (23.63 mM; Ultrasonic )

——

——

(-20℃)

With Ice Pack

≥ 2 years